Abstracts tagged "RANK/RANKL pathway and rheumatoid arthritis (RA)"

Abstract Number: 3101 • 2015 ACR/ARHP Annual Meeting
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Sclerostin Are Related to Joint Destruction in Early Rheumatoid Arthritis Unrelated to Polymorphisms of the Genes
Antonia Boman¹, Heidi Kokkonen², Ewa Berglin¹, Lisbeth Ärlestig¹ and Solbritt Rantapaa-Dahlqvist³, ¹Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ³Department of Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by joint inflammation and destruction of cartilage and bone. The destructive process is related to autoantibodies, genetic polymorphisms involving…
Abstract Number: 1000 • 2014 ACR/ARHP Annual Meeting
Pathogenic Role of CXC Chemokine receptor 3-Positive B Cells in Bone Destruction of Rheumatoid Arthritis
Yuri Hirosaki, Hiroaki Niiro, Shun-ichiro Ota, Naoko Ueki, Hirofumi Tsuzuki, Kumiko Noda, Siamak Jabbarzadeh-Tabrizi, Hiroki Mitoma, Yojiro Arinobu, Mitsuteru Akahoshi, Hiroshi Tsukamoto and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose ：B cells can function as potent effector cells by production of autoantibody, immune complex formation and inflammatory cytokines. Clinical efficacy of B-cell depletion therapy…
Abstract Number: 914 • 2013 ACR/ARHP Annual Meeting
Accentuated Expression Of RANKL In Switched Memory B Cells From Patients With Rheumatoid Arthritis
Yuri Hirosaki, Hiroaki Niiro, Shun-ichiro Ota, Naoko Ueki, Hirofumi Tsuzuki, Siamak Jabbarzadeh-Tabrizi, Kumiko Noda, Naoyasu Ueda, Naoyasu Ueda, Atsushi Tanaka, Masahiro Ayano, Sho Ueda, Satomi Hisamoto, Daisuke Oryoji, Mitsuteru Akahoshi, Yojiro Arinobu, Hiroshi Tsukamoto, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Clinical efficacy of B-cell depletion therapy underscores a pathogenic role of B cells in autoimmune diseases such as rheumatoid arthritis (RA). In addition to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].